Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company Plc (NYSE: PRGO) is a global provider of quality, affordable self-care products and over-the-counter health solutions. This dedicated news hub offers investors and industry professionals centralized access to official announcements, financial disclosures, and market developments.
Track Perrigo's strategic initiatives through verified press releases covering earnings results, product innovations, regulatory milestones, and partnership announcements. Our curated collection provides essential insights into the company's operations across key markets in North America, Europe, and global consumer health sectors.
Discover updates on Perrigo's store-brand leadership, branded OTC developments, and manufacturing advancements. The resource serves as a reliable reference for monitoring the company's progress in delivering accessible healthcare solutions through major retail partnerships and direct-to-consumer channels.
Bookmark this page for streamlined access to Perrigo's latest business updates, including analysis of market positioning in consumer self-care categories and operational efficiency programs. Stay informed about one of the OTC sector's most established innovators through verified, up-to-date information sources.
Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, has announced a quarterly dividend of $0.276 per share. The dividend is payable on September 17, 2024, to shareholders of record on August 30, 2024. Perrigo is a prominent provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions, focusing on empowering consumers to prevent or treat self-manageable conditions.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present on Wednesday, August 14 at 3:30 PM EDT.
Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. Perrigo is known for offering over-the-counter (OTC) health and wellness solutions that empower consumers to proactively prevent or treat self-manageable conditions, enhancing individual well-being.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced its plan to release second quarter 2024 financial results on Friday, August 2, 2024. The company will host a conference call at 8:30 A.M. (EST) on the same day. Interested parties can access the earnings conference call via webcast on Perrigo's investor relations website or by phone. A taped replay of the call will be available from approximately 12:00 P.M. (EST) on August 2 until midnight on August 9, 2024.
Perrigo specializes in over-the-counter (OTC) health and wellness solutions, focusing on empowering consumers to proactively prevent or treat self-manageable conditions.
Perrigo Company plc (NYSE PRGO), a leader in Consumer Self-Care Products, has finalized the sale of its HRA Pharma Rare Diseases business to Esteve Healthcare for a total of up to €275 million. The deal includes an upfront cash payment of €190 million with adjustments, and potential earnout payments of up to €85 million based on sales milestones. Proceeds are expected to be used for debt repayment. In 2023, the divested business generated €50 million in net sales and €20 million in adjusted EBITDA. This transaction was anticipated in Perrigo's 2024 financial outlook.
Perrigo Company (NYSE: PRGO), a leader in Consumer Self-Care Products, announced that its President and CEO, Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will present at the Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference. The event is scheduled to be held virtually on June 11, 2024, at 1:30 PM EDT. The presentation will be accessible via a webcast on Perrigo's investor relations webpage.
Perrigo reported first quarter 2024 financial results with adjusted diluted earnings per share above projections due to infant formula shipments. The company reaffirmed its 2024 financial outlook and highlighted progress in building One Perrigo. However, first quarter net sales declined 8.4%, with organic net sales decreasing 7.0%, primarily from lower infant formula sales and SKU prioritization actions. Gross margin declined, and adjusted EPS decreased by 35.6%. The company launched Opill®, the first over-the-counter birth control pill in the US. Perrigo also announced the divestment of its HRA Rare Diseases Business. Project Energize aims to drive growth and efficiency, expecting $140-$170 million in annual savings by 2026. An executive transition was announced for the Consumer Self-Care International Business. Cash equivalents were $659 million, and the company maintained its fiscal year 2024 outlook.
Perrigo Company plc announced an executive transition within its Consumer Self-Care International (CSCI) Business. Svend Andersen, EVP and President of CSCI, will retire in December, with Roberto Khoury taking over. Khoury, a seasoned consumer health professional, will bring his vast experience to lead the CSCI segment. Andersen will work alongside Khoury until August for a smooth handover. Khoury's background includes leadership roles at Kenvue and L'Oréal, emphasizing his expertise in the consumer products industry.
Perrigo Company plc (NYSE: PRGO) declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024. Perrigo is a global provider of Consumer Self-Care Products and OTC health solutions.
